The immuno-oncology drug developer, which is backed by Celgene and GV, floated above its range and has since seen its share price rise 75%.

The pharmaceutical development technology provider has received funding from investors including Google and series A backer Tencent.

The Biogen-backed Duchenne muscular dystrophy drug developer saw its share price rise sharply after securing approximately $125m in its IPO.

Applied Ventures invested in the Ultivue as part of a series B round that will be used to develop its biomarker detection technology.

The oncological surgical developer has been spun out from ICL with investment from China and Hong Kong.

Michigan’s Armune Bioscience has been bought by Exact Science, which plans to expand its cancer diagnostics range with Armune’s prostate cancer test.

The round will enable medical apparel producer Figs to buy out its earlier investors, which include Crocs, leaving Tulco its only external backer.

Neuspera is developing technology to power devices such as pacemakers by manipulating the direction of electromagnetic waves, exploiting research at Stanford University.